Head-to-head comparison
Pallas Health vs Shapely
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Pallas Health names all six of the pharmacies that dispense for it and two prescribing clinicians whose NPIs verify in the federal registry — then sells every GLP-1 on a single twelve-week prepay, so the advertised “/mo average” is one $597 or $897 charge divided by three.
$199/mo (see conditions) sema · $299/mo (see conditions) tirz · Verified August 2026
Marked down on: There is no month-to-month rung for either compounded molecule — the funnel renders no cadence selector — so the advertised “$199/mo average” is a single $597 charge every twelve weeks divided by three
Desk Score
Shapely is a GLP-1 telehealth platform founded by Dr.
Marked down on: Currently available only in California, Florida, New York, and Texas — 46 states unserved despite announced expansion
Pallas Health takes this head-to-head with the higher Desk Score, 87/100 (B+) against 63/100 (C) for Shapely. Shapely still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Pallas Health
87/100
B+
Shapely
63/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Pallas Health | Shapely |
|---|---|---|
| Semaglutide | $199/mosee conditions$199/mo average (compounded injectable; $597 billed every 12 weeks after $139 for the first 4 weeks; no month-to-month tier is sold) | Not listed on Shapely's site (checked July 2026) |
| Tirzepatide | $299/mosee conditions$299/mo average (compounded injectable; $897 billed every 12 weeks after $179 for the first 4 weeks; no month-to-month tier is sold) | Not listed on Shapely's site (checked July 2026) |
| Coverage | All 50 states + DC (async in 43; 7 states plus DC require one video visit) | 4 states |
| Brand-name | Yes | Yes |
| Oral option | Injectable only | Injectable only |
| Best for | Readers who weight named pharmacies and independently verifiable prescribers above cash-flow flexibility, and who can absorb a $597 or $897 charge every twelve weeks rather than a monthly one. | Insurance-accepted telehealth with compounded sema $99/mo and tirz $166/mo; CA, FL, NY, TX (expanding). |
| Desk Score | 87/100B+ | 63/100C |
The verdict
Desk pick — Pallas HealthPallas Health takes this head-to-head with the higher Desk Score, 87/100 (B+) against 63/100 (C) for Shapely. Shapely still holds its ground where its strengths line up with yours.
Choose Pallas Health if…
Readers who weight named pharmacies and independently verifiable prescribers above cash-flow flexibility, and who can absorb a $597 or $897 charge every twelve weeks rather than a monthly one.
$199/mo (see conditions) sema · $299/mo (see conditions) tirz · All 50 states + DC (async in 43; 7 states plus DC require one video visit)
Choose Shapely if…
Insurance-accepted telehealth with compounded sema $99/mo and tirz $166/mo; CA, FL, NY, TX (expanding).
4 states
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Pallas Health · Shapely.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs Pallas Health
- CoreAge Rx vs Shapely
- Pallas Health vs Sesame Care
- Shapely vs Vaylen
- Eden vs Pallas Health
- Eden vs Shapely
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.